Job title: CBO
Dr. Vafa joined TeneoBio as Chief Business Officer in February 2016. He has more than 15 years of global business and scientific experience in biotechnology and pharmaceutical drug discovery, asset evaluation, transactions and licensing. Prior to joining TeneoBio, Dr. Vafa was the Director of Strategy and Scientific Partnerships at Janssen Pharmaceutical Companies of Johnson and Johnson and the Biotechnology and Oncology Lead at the London Innovation Center of J&J. Dr. Vafa earned his doctorate at Georgetown University, his MBA from the Villanova University School of Business, and his B.S. from the University of California at Irvine. He completed his post-doctoral fellowships at The Scripps Research Institute (TSRI) and the Salk Institute for Biological Studies in La Jolla, California.
A Novel Multispecific T Cell Engager Platform for a Better Therapeutic Window 9:30 am
• TeneoBio’s sequence-based discovery: Profiling the B-cell repertoire of human Ig transgenic rats for diverse leads against target antigens of interest • Identifying and optimizing multi-specific leads for a novel CD3-based T-cell engager platform • Mitigating safety risk with T-cell engagers that maximize target cancer cytotoxicity and minimize cytokine release • Improving the therapeutic window…Read more
day: Day Two